Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Recurrent Low-Grade or Borderline Ovarian Cancer
NCT00505661Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2003
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate. Started Sep 2003; status: terminated.
02
Drugs
letrozole
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00505661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505661.